The Cell Reprogramming Market was valued at USD 406.6 Million in 2024, and is projected to reach USD 664.2 Million by 2030, rising at a CAGR of 8.55%. Factors, such as increasing adoption of cell reprogramming in cancer research and growing focus on cell reprogramming, are expected to drive market growth. In addition, emphasis on collaborations and partnerships among key players is anticipated to boost market growth. Advancements in the mRNA reprogramming technique allow rapid, safe, and efficient generation of clinical-grade human iPS cells using somatic tissue. In addition, as mRNA is lower in size, the transfection process is simpler than other reprogramming vectors. When utilizing difficult-to-reprogram samples, mRNA reprogramming improves reprogramming efficiency by 1%.
Furthermore, this method can generate high-quality human iPS cells from somatic tissue more rapidly and safely, which increases the demand for mRNA reprogramming technology. Furthermore, there is the capability to reprogram human stem cells back to a naive state, allowing replication of the earliest developmental stages. For instance, in March 2022, researchers at the Babraham Institute identified key factors facilitating this reprogramming process. This new knowledge streamlines and expedites the generation of naive pluripotent stem cells for researchers. Moreover, cell reprogramming is experiencing growth due to significant government and public funding. This backing is a response to various benefits it offers to the healthcare sector, particularly in terms of its potential applications in medicine.
Furthermore, cell reprogramming has recently been repositioned from the lab to clinic by researchers. This shift is prominent in various clinical & academic research initiatives, encompassing regenerative medicine, disease modeling, and studies related to medication toxicity & drug discovery. The clinical utility of cell reprogramming, especially in regenerative medicine, has been significant. Increased strategic initiatives aimed at innovative product development through cell reprogramming is due to a growth in the research and academic institute segment. For instance, the California Institute for Regenerative Medicine funded research groups to advance cellular reprogramming into therapeutic applications with a clinical focus.
This product will be delivered within 2 business days.
Furthermore, this method can generate high-quality human iPS cells from somatic tissue more rapidly and safely, which increases the demand for mRNA reprogramming technology. Furthermore, there is the capability to reprogram human stem cells back to a naive state, allowing replication of the earliest developmental stages. For instance, in March 2022, researchers at the Babraham Institute identified key factors facilitating this reprogramming process. This new knowledge streamlines and expedites the generation of naive pluripotent stem cells for researchers. Moreover, cell reprogramming is experiencing growth due to significant government and public funding. This backing is a response to various benefits it offers to the healthcare sector, particularly in terms of its potential applications in medicine.
Furthermore, cell reprogramming has recently been repositioned from the lab to clinic by researchers. This shift is prominent in various clinical & academic research initiatives, encompassing regenerative medicine, disease modeling, and studies related to medication toxicity & drug discovery. The clinical utility of cell reprogramming, especially in regenerative medicine, has been significant. Increased strategic initiatives aimed at innovative product development through cell reprogramming is due to a growth in the research and academic institute segment. For instance, the California Institute for Regenerative Medicine funded research groups to advance cellular reprogramming into therapeutic applications with a clinical focus.
Cell Reprogramming Market Report Highlights
- The mRNA reprogramming technology segment held the largest revenue share of 32.63% in 2024, due to the ease of use, speed, safety, and efficiency while generating high-quality human iPS cells from somatic tissue.
- The research application segment led the market with a share of 67.30% in 2024. One of the main factors driving its growth include ongoing research in the field of cell reprogramming using stem cells.
- The research & academic institute end-use segment held a revenue share of 67.30% in 2024. The growth is due to usage of cell reprogramming in a various clinical & academic research initiatives, including those involving regenerative therapies, disease modeling, and drug toxicity/drug discovery studies.
- North America dominated the global industry in 2024, with a revenue share of 39.69%, owing to the presence of key players in this region.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. Technology Business Analysis
Chapter 5. Application Business Analysis
Chapter 6. End-use Business Analysis
Chapter 7. Regional Business Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Cell Reprogramming market report include:- Thermo Fisher Scientific Inc.
- Allele Biotechnology and Pharmaceuticals Inc.
- ALSTEM
- STEMCELL Technologies
- Merck KGaA
- Bio-Techne
- REPROCELL Inc.
- Lonza
- FUJIFILM Corporation (Fujifilm Cellular Dynamics)
- Mogrify Limited
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 120 |
Published | April 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 406.6 Million |
Forecasted Market Value ( USD | $ 664.2 Million |
Compound Annual Growth Rate | 8.5% |
Regions Covered | Global |
No. of Companies Mentioned | 11 |